Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Xcel Energy Inc — how do they compare? Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B), while Xcel Energy Inc trades at $76.24 (market cap $48.02B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.8× Xcel Energy Inc's market cap, and Xcel Energy Inc pays a 3.08% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| VRTX | XEL | |
|---|---|---|
Market Cap | $134.06B | $48.02B |
Sector | Health | Utilities |
52-Week High | $557.96 | $83.91 |
52-Week Low | $376.62 | $72.05 |
Enterprise Value | $128.18B | $86.33B |
Dividend Yield | — | 3.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
XEL trades at $76.88, up 1.53% on the day, with a bearish technical signal but strong analyst consensus. Recent Q2 2026 earnings beat estimates at $0.93 per share. The company maintains solid profitability with a 15.28% net income margin and is executing a $70B+ capital investment plan through 2030 to drive growth. Dividend payments remain consistent at $0.59 quarterly.
Outlook is positive with a $92 consensus price target, though risks include high capital expenditures, regulatory scrutiny from wildfire lawsuits, and rising interest rates. The stock offers stable income and growth potential but faces execution and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
